- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
Session Title: Toric IOL Outcomes
Session Date/Time: Monday 07/10/2013 | 16:30-18:30
Paper Time: 17:18
Venue: Auditorium (First Floor)
First Author: : L.Cadarso SPAIN
Co Author(s): : B. Pita A. Rodriguez
to evaluate the clinical outcomes after implantation a new hydrophobic toric intraocular lens in patients having routine cataract surgery and preexisiting corneal astigmatism.
5 European centers
Patients who would benefit of an enVista® toric (Model MX60T) implantation (IOL SE power range 15.0D to 25.5D and IOL CYL power of 1.25D, 2.00D and 2.75 D) were prospectively included in this study. Routine examinations were performed 1 to 2 months after surgery measuring uncorrected (UDVA) and best corrected (CDVA) visual acuity, manifest refraction including residual refractive cylinder, and IOL rotation.
The study enrolled 58 eyes of 46 patients. 48 eyes were evaluated 4-10 weeks follow-up after surgery. Preoperative corneal astigmatism ranged from 0.85 to 2.95D. The mean cylinder reduction was approximately 85% with a mean absolute post-operative refractive cylinder of 0.42 (SD 0.38D). Mean UDVA was 0.14 logMAR (20/25 Snellen), mean CDVA was 0.05 logMAR (20/20 Snellen). Mean absolute IOL rotation from surgery was 3.6 degrees with rotation less than 12° in 100% of eyes.
Implantation of the enVista® toric is a safe and effective method to correct corneal astigmatism in patients having routine cataract surgery. The lens shows excellent post operative refractive predictability and rotational stability.
... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented
Please wait while information is loading.